David Altshuler (Endpoints file photo)

#ASH20: David Alt­shuler and the Ver­tex/CRISPR team hit a his­toric mile­stone in the hunt for a cu­ra­tive gene edit­ing ap­proach to sick­le cell dis­ease, be­ta tha­lassemia

Back in the mid-80s, David Alt­shuler worked in Richard Mul­li­gan’s fa­mous Har­vard lab, fo­cused on he­mo­glo­binopathies and the glim­mer­ing promise of a gene ther­a­py for sick­le cell dis­ease.

To­day, 35 years lat­er, the Broad co-founder and chief sci­en­tist at Ver­tex and his part­ners at CRISPR Ther­a­peu­tics have reached a sign post on the world’s most ad­vanced gene edit­ing pro­gram that points to a po­ten­tial cure for both sick­le cell dis­ease and be­ta tha­lassemia. And Alt­shuler can see the fin­ish line ahead.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.